0001492298-24-000017.txt : 20240613 0001492298-24-000017.hdr.sgml : 20240613 20240613172012 ACCESSION NUMBER: 0001492298-24-000017 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240613 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240613 DATE AS OF CHANGE: 20240613 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sabra Health Care REIT, Inc. CENTRAL INDEX KEY: 0001492298 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] ORGANIZATION NAME: 05 Real Estate & Construction IRS NUMBER: 272560479 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34950 FILM NUMBER: 241042197 BUSINESS ADDRESS: STREET 1: 18500 VON KARMAN STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 888-393-8248 MAIL ADDRESS: STREET 1: 18500 VON KARMAN STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 8-K 1 sbra-20240613.htm 8-K sbra-20240613
false000149229800014922982024-06-132024-06-13

  
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 13, 2024
SABRA HEALTH CARE REIT, INC.
(Exact name of registrant as specified in its charter)
 
Maryland 001-34950 27-2560479
(State of
Incorporation)		 (Commission
File Number)		 (I.R.S. Employer
Identification No.)
 
1781 Flight Way
Tustin
CA
92782
(Address of principal executive offices)(Zip Code)
Registrant's telephone number including area code: (888) 393-8248  
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common stock, $0.01 par valueSBRAThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.07
Submission of Matters to a Vote of Security Holders.
(a) The annual meeting of stockholders of the Company (the “Annual Meeting”) was held on June 13, 2024.
(b) At the Annual Meeting, the Company’s stockholders (i) elected the eight nominees identified in the table below to the Board of Directors of the Company to serve until the Company’s 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified (“Election of Directors”), (ii) ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 (“Auditor Ratification”) and (iii) approved, on an advisory basis, the compensation of the Company’s named executive officers as set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2024 (“Advisory Compensation Vote”). Set forth below are the final voting tallies for the Annual Meeting:

Election of Directors
For
Against
Abstain
Broker Non-Votes
Craig A. Barbarosh
178,428,5165,521,821274,58520,348,072
Katie Cusack
182,845,0241,157,705222,19320,348,072
Michael J. Foster
178,035,7395,953,979235,20420,348,072
Lynne S. Katzmann
178,856,0985,143,790225,03420,348,072
Ann Kono
183,255,819746,479222,62420,348,072
Jeffrey A. Malehorn
181,745,9032,233,784245,23520,348,072
Richard K. Matros
174,454,7807,542,8222,227,32020,348,072
Clifton J. Porter II
182,591,7581,400,982232,18220,348,072

Auditor Ratification
For
Against
Abstain
Broker Non-Votes
202,131,0492,268,764173,181
—

Advisory Compensation Vote
For
Against
Abstain
Broker Non-Votes
173,769,73710,001,666453,51920,348,072





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
SABRA HEALTH CARE REIT, INC.
Date: June 13, 2024/S/ MICHAEL COSTA
Name: Michael Costa
Title: Chief Financial Officer, Secretary and
Executive Vice President




 EX-101.SCH 2 sbra-20240613.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 sbra-20240613_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Written Communications Written Communications Title of 12(b) Security Title of 12(b) Security Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Current Fiscal Year End Date Current Fiscal Year End Date Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 4 sbra-20240613_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
Jun. 13, 2024
Cover [Abstract]  
Title of 12(b) Security Common stock, $0.01 par value
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 13, 2024
Entity Registrant Name SABRA HEALTH CARE REIT, INC.
Entity Central Index Key 0001492298
Entity Incorporation, State or Country Code MD
Entity File Number 001-34950
Entity Tax Identification Number 27-2560479
Entity Address, Address Line One 1781 Flight Way
Entity Address, City or Town Tustin
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92782
City Area Code 888
Local Phone Number 393-8248
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Trading Symbol SBRA
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Sheet http://www.sabrahealth.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports sbra-20240613.htm sbra-20240613.xsd sbra-20240613_lab.xml sbra-20240613_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sbra-20240613.htm": { "nsprefix": "sbra", "nsuri": "http://www.sabrahealth.com/20240613", "dts": { "inline": { "local": [ "sbra-20240613.htm" ] }, "schema": { "local": [ "sbra-20240613.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "sbra-20240613_lab.xml" ] }, "presentationLink": { "local": [ "sbra-20240613_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.sabrahealth.com/role/DocumentandEntityInformation", "longName": "0000001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:Security12bTitle", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20240613.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:Security12bTitle", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20240613.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001492298-24-000017-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001492298-24-000017-xbrl.zip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end XML 16 sbra-20240613_htm.xml IDEA: XBRL DOCUMENT 0001492298 2024-06-13 2024-06-13 false 0001492298 8-K 2024-06-13 SABRA HEALTH CARE REIT, INC. MD 001-34950 27-2560479 1781 Flight Way Tustin CA 92782 888 393-8248 false false false false Common stock, $0.01 par value SBRA NASDAQ false